Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.39 USD | -0.71% | -9.15% | +12.10% |
Financials (USD)
Sales 2024 * | 189M | Sales 2025 * | 171M | Capitalization | 291M |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | -63M | EV / Sales 2024 * | 1.54 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.7 x |
P/E ratio 2024 * |
-4.83
x | P/E ratio 2025 * |
-4.88
x | Employees | 167 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.79% |
Latest transcript on Akebia Therapeutics, Inc.
1 day | -0.71% | ||
1 week | -9.15% | ||
Current month | -24.04% | ||
1 month | -26.46% | ||
3 months | -0.71% | ||
6 months | +60.36% | ||
Current year | +12.10% |
Managers | Title | Age | Since |
---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 13-06-30 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 22-03-31 |
Michel Dahan
COO | Chief Operating Officer | 45 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 18-12-11 |
Adrian Adams
CHM | Chairman | 73 | 18-12-11 |
Director/Board Member | 65 | 21-02-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-16 | 1.4 | +0.72% | 4,129,457 |
24-04-15 | 1.39 | -4.79% | 3,897,726 |
24-04-12 | 1.46 | -4.58% | 4,105,836 |
24-04-11 | 1.53 | -1.92% | 3,154,704 |
24-04-10 | 1.56 | +1.30% | 5,435,326 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.10% | 293M | |
-3.39% | 102B | |
+2.61% | 96.09B | |
-1.02% | 22.05B | |
-18.14% | 20.81B | |
-6.87% | 19.06B | |
-40.70% | 16.05B | |
-26.89% | 14.01B | |
+1.12% | 13.38B | |
+22.25% | 11.01B |
- Stock Market
- Equities
- AKBA Stock